TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00506337
Drug: Qingyi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD.
Study: NCT04020588
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered for 6 weeks
Study: NCT04020588
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be administered for 6 weeks
Study: NCT04020588
Drug: Minocycline 100mg
Normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered for 6 weeks
Study: NCT02359344
Drug: CNV1014802
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215096
Drug: GSK2636771
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
Study: NCT00704678
Drug: SBR759
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g tid
Study: NCT03784703
Drug: Rosuvastatin 10 Mg Oral Tablet
Normalized name: rosuvastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
Study: NCT00076206
Drug: CCI-779
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00076206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01747148
Drug: AVI-7100 versus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose-escalating AVI-7100 versus placebo
Study: NCT02705872
Drug: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
Study: NCT02705872
Drug: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
Study: NCT03935295
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prepared by Ipsen for use as control
Study: NCT01997853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
Study: NCT03540030
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT00569270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Study: NCT03715101
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Open-label, one-sequence, multiple administration
Study: NCT02058173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02985437
Drug: Surfactants
Normalized name: surfactants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04286399
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study: NCT04032652
Drug: Rectal dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
Study: NCT02388178
Drug: Control toothpaste containing no anti-cavity ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study: NCT03913468
Drug: Intravenous Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
Study: NCT02388178
Drug: Fluoride toothpaste containing fluoride as the anti-cavity ingredient
Normalized name: sodium fluoride Mouthwash [Oral B Anti-Cavity]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study: NCT01088750
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01088750
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00018551
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02219321
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
Study: NCT02655133
Drug: Physiologic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
Study: NCT04534582
Drug: EU-Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: healthy volunteers receive EU-Prolia® (60mg) once
Study: NCT04534582
Drug: US-Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: healthy volunteers receive US-Prolia® (60mg) once
Study: NCT04534582
Drug: CN-Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: healthy volunteers receive CN-Prolia® (60mg) once
Study: NCT02389309
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04551885
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT03939026
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT01536743
Drug: PD0332991
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle).
Study: NCT03754725
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo orally
Study: NCT01259765
Drug: VHH batch 203027
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
Study: NCT01259765
Drug: Placebo product
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
Study: NCT01313858
Drug: Simponi®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01313858
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given concomitantly with Simponi®
Study: NCT01126801
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral estradiol 1.0 mg/day for four weeks.
Study: NCT00313300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0, twice daily, 26 weeks
Study: NCT02436304
Drug: EXE844 Sterile Otic Suspension, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254941
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy
Study: NCT01349088
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive capecitabine at 2000 mg/m2.
Study: NCT00006381
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00249821
Drug: Saizen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Study: NCT03836599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
Study: NCT02202187
Drug: GSK2140944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Study Drug
Study: NCT03764007
Drug: 18F-Fluorocholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously
Study: NCT00249821
Drug: Saizen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Study: NCT03995121
Drug: [11C]APP311
Approvals — FDA: no, EMA: no, PMDA: no
Description: It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Study: NCT01500122
Drug: RhuDex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions.
Study: NCT02280070
Drug: l-LV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Study: NCT00659048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00576017
Drug: Fentanyl-TTS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03126916
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03126916
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00525967
Drug: Methadone plus Acetaminophen or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
Study: NCT00357357
Drug: HF0220
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT01669499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00306215
Drug: CCX282-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX282-B or placebo capsules
Study: NCT01031381
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
Study: NCT01210131
Drug: [18F]HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT02995031
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
Study: NCT02995031
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT03567577
Drug: 0.9% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
Study: NCT01640912
Drug: RXI-109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intradermal injection of RXI-109 at incision sites
Study: NCT01640912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intradermal injection of placebo at incision sites
Study: NCT01651858
Drug: Nurigra Chewable tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of 100mg, once a day
Study: NCT02081404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02698748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
Study: NCT00978549
Drug: steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01878942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to LSD~per os
Study: NCT02720770
Drug: norditropine simplex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01823146
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
Study: NCT00398918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT02140450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears, 2 drops, 1-2 hours before intravitreal injection
Study: NCT01350921
Drug: Venlaflaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg oral immediate release tablets, administered twice daily on days 4-8
Study: NCT00365261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 2 to 3 mg po at bedtime
Study: NCT00366977
Drug: NRT patches
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03644095
Drug: Mucinex® SE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
Study: NCT01802086
Drug: Miniderm cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT02833350
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Study: NCT02833350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Study: NCT02668692
Drug: LEO 80185 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Study: NCT04432506
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03327012
Drug: Treatment of Panlongqi placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
Study: NCT00075595
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00075595
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00075595
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01957774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02650635
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00569465
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg, once a day
Study: NCT00569465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 vials a day
Study: NCT01604408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04239092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
Study: NCT03242889
Drug: DARA SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
Study: NCT02508857
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
Study: NCT02484833
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02023593
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT01955564
Drug: NW-3509a
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT03758443
Drug: TD-1473 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT03758443
Drug: TD-1473 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT03758443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT04432259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT00471146
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02387710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00120523
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCS
Study: NCT00000304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00949130
Drug: NXL103
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID for 7-14 days
Study: NCT03780543
Drug: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
Study: NCT00092157
Drug: MK0733, simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092157
Drug: Comparator: simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03987022
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively
Study: NCT03987022
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of narcotic for pain control postoperatively